cost of glp-1 drugs The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss GLP-1s driving healthcare cost hikes,

Clinicians may favor drugs that are more likely to be covered, even if they are not the first clinical choice

However, starting around October 2024, claims began to be denied correctly as an exclusion

Diabetes Obes Metab 15: 713720, 2013

Overall, anti-metabolic drugs performed the best in both aspects, with odds ratios of 2.15 and 1.35, while anti-fibrotic drugs showed ratios of 0.86 and 1.11

A significant challenge in interpreting the data arose from the heterogeneity in the GLP-1RA doses administered and the variable reporting of these doses

Specifically, the review found that compared to people on treatment plans without GLP-1, those taking the medications had 0.44% lower HbA1c (an important marker of blood sugar) and were almost twice as likely to hit the recommended HbA1c target